Your browser doesn't support javascript.
loading
Relationship between HuR and tumor drug resistance
Ma, Qiancheng; Zhao, Jie; Zhu, Qing; Lu, Qiliang; Lei, Xiangxiang; Sun, Wen; Huang, Dongsheng; Xu, Qiuran.
Afiliação
  • Ma, Qiancheng; Zhejiang University of Technology. College of Biotechnology and Bioengineering. Hangzhou. China
  • Zhao, Jie; Zhejiang University of Technology. College of Biotechnology and Bioengineering. Hangzhou. China
  • Zhu, Qing; Zhejiang University of Technology. College of Biotechnology and Bioengineering. Hangzhou. China
  • Lu, Qiliang; Qingdao University. Qingdao Medical College. Qingdao. China
  • Lei, Xiangxiang; Hangzhou Medical College. Hangzhou. China
  • Sun, Wen; Zhejiang Chinese Medical University. Hangzhou. China
  • Huang, Dongsheng; Hangzhou Medical College. Affiliated People’s Hospital. Zhejiang Provincial People’s Hospital. Hangzhou. China
  • Xu, Qiuran; Hangzhou Medical College. Affiliated People’s Hospital. Zhejiang Provincial People’s Hospital. Hangzhou. China
Clin. transl. oncol. (Print) ; 25(7): 1999-2014, jul. 2023. ilus
Article em En | IBECS | ID: ibc-222374
Biblioteca responsável: ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Human resistance protein R (HuR), also known as embryonic lethal abnormal visual-like protein (ELAVL1), is an RNA-binding protein widely expressed in vivo that affects the mRNA stability of targeted and is involved in post-transcriptional regulation. Recent studies have shown that HuR is aberrantly expressed in different human cancers and is an essential factor in poor clinical prognosis. The role of HuR in numerous tumors suggests that it could be a new target for tumor therapy and as a marker for efficacy and prognostic assessment. This review focuses on the relationship between HuR and drug resistance in different tumors and briefly describes the structure, function, and inhibitors of HuR. We summarize the mechanisms by which HuR causes tumor resistance and the molecular targets affected (AU)
Assuntos
Palavras-chave
Buscar no Google
Base de dados: IBECS Assunto principal: Resistencia a Medicamentos Antineoplásicos / Proteína Semelhante a ELAV 1 / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Buscar no Google
Base de dados: IBECS Assunto principal: Resistencia a Medicamentos Antineoplásicos / Proteína Semelhante a ELAV 1 / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article